Immunome
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | 14.0m | 8.5m | 1.3m | 19.4m |
% growth | - | - | - | - | (40 %) | (84 %) | 1352 % |
EBITDA | (12.3m) | (24.7m) | (36.3m) | 52.8m | (254m) | - | - |
% EBITDA margin | - | - | - | 377 % | (3000 %) | - | - |
Profit | (17.8m) | (24.7m) | (36.9m) | (107m) | (235m) | (184m) | (215m) |
% profit margin | - | - | - | (762 %) | (2773 %) | (13773 %) | (1110 %) |
EV / revenue | - | - | - | 32.6x | 107.7x | 683.9x | 47.1x |
EV / EBITDA | -8.3x | -6.3x | -0.7x | 8.7x | -3.6x | - | - |
R&D budget | 7.5m | 14.1m | 23.3m | 23.1m | - | - | - |
R&D % of revenue | - | - | - | 165 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Debt | ||
N/A | N/A | Seed | |
$445k | Early VC | ||
N/A | N/A | Seed | |
N/A | $735k | Debt | |
$467k | Debt | ||
$200k | Debt | ||
$7.2m | Series A | ||
N/A | N/A | Series A | |
N/A | $9.3m | Early VC | |
$11.0m | Early VC | ||
N/A | N/A | IPO | |
N/A | $17.6m | Grant | |
* | $125m | Private Placement VC | |
* | N/A | $200m | Post IPO Equity |
Total Funding | $171m |
Recent News about Immunome
EditImmunome is a biotechnology company focused on developing first-in-class therapeutics by harnessing the power of the immune system. The company operates in the biopharmaceutical market and serves clients in the healthcare and medical research sectors. Immunome's proprietary discovery platform identifies novel therapeutic antibodies and their targets by analyzing the immune systems of patients who have successfully fought off diseases. This approach aims to create groundbreaking treatments for various conditions. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and potential future sales of approved therapies. Immunome's team includes experts in clinical oncology and medical research, ensuring a strong foundation for scientific innovation.
Keywords: biotechnology, therapeutics, immune system, antibodies, biopharmaceutical, healthcare, medical research, discovery platform, oncology, innovation.